Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.LFMD · Entity 6521 | Chief Financial Officer | August 22, 2025 | August 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date August 22, 2025 · Filed August 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 426,554 |
Reported balance
After 2025-08-22 transaction · row 1
1 source rowRow 1 · 2025-08-22 · Grant · Acquired 87,000 · Balance 426,554 F1: Represents grant of performance stock which vested on August 22, 2025 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of performance stock which vested on August 22, 2025
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2025 Filed Aug 26, 2025 22:11 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 87,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000910 · form4.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,554 F1 · price: Represents grant of performance stock which vested on August 22, 2025 Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 22:18 UTC | LifeMD, Inc. LFMD · Entity 6521 | SaleCommon Stock | 50,000 | $14.01 | $700,495.00 |
DisclosureSEC source: 0000912282-25-000692 · form4.xml · nonDerivative · entry 2 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 339,554 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 and $14.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 22:18 UTC | LifeMD, Inc. LFMD · Entity 6521 | SaleCommon Stock | 75,000 | $13.09 | $981,945.00 |
DisclosureSEC source: 0000912282-25-000692 · form4.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 389,554 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.57 and $13.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the ranges set forth above. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 21:45 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000361 · form4.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 464,554 F1 · price: Represents grant of performance stock which vested on March 31, 2025. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 22:03 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 87,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000281 · form4.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 389,554 F1 · price: Represents grant of performance stock which vested on March 7, 2025. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 17:17 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-24-000009 · primary_doc.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,554 F1 · price: Performance shares vested on March 21, 2024. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:02 UTC | LifeMD, Inc. LFMD · Entity 6521 | Exercise / conversionRestricted Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-23-000047 · primary_doc.xml · derivative · entry 6 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock converts into common stock on a one-for-one basis. F1 · derivative.exercise_date: The options are being cancelled in exchange for 125,000 restricted shares, with 50,000 vesting on January 1, 2024 and 75,0000 vesting on January 1, 2025, and performance shares to be reported on settlement. In addition, vesting accelerated immediately on 25,000 restricted stock previously granted to Mr. Benathen on January 27, 2022. The option vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following February 4, 2021. F1 · derivative.expiration_date: The options are being cancelled in exchange for 125,000 restricted shares, with 50,000 vesting on January 1, 2024 and 75,0000 vesting on January 1, 2025, and performance shares to be reported on settlement. In addition, vesting accelerated immediately on 25,000 restricted stock previously granted to Mr. Benathen on January 27, 2022. The option vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following February 4, 2021. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:02 UTC | LifeMD, Inc. LFMD · Entity 6521 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,000 | Not disclosed Strike: $21.20 | Not disclosed |
DisclosureSEC source: 0001362118-23-000047 · primary_doc.xml · derivative · entry 4 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · price: The options are being cancelled in exchange for 125,000 restricted shares, with 50,000 vesting on January 1, 2024 and 75,0000 vesting on January 1, 2025, and performance shares to be reported on settlement. In addition, vesting accelerated immediately on 25,000 restricted stock previously granted to Mr. Benathen on January 27, 2022. The option vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following February 4, 2021. F1 · derivative.exercise_date: The options are being cancelled in exchange for 125,000 restricted shares, with 50,000 vesting on January 1, 2024 and 75,0000 vesting on January 1, 2025, and performance shares to be reported on settlement. In addition, vesting accelerated immediately on 25,000 restricted stock previously granted to Mr. Benathen on January 27, 2022. The option vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following February 4, 2021. F1 · derivative.expiration_date: The options are being cancelled in exchange for 125,000 restricted shares, with 50,000 vesting on January 1, 2024 and 75,0000 vesting on January 1, 2025, and performance shares to be reported on settlement. In addition, vesting accelerated immediately on 25,000 restricted stock previously granted to Mr. Benathen on January 27, 2022. The option vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following February 4, 2021. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:02 UTC | LifeMD, Inc. LFMD · Entity 6521 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-23-000047 · primary_doc.xml · nonDerivative · entry 3 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 16:02 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001362118-23-000047 · primary_doc.xml · nonDerivative · entry 2 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,554 F1 · price: The options are being cancelled in exchange for 125,000 restricted shares, with 50,000 vesting on January 1, 2024 and 75,0000 vesting on January 1, 2025, and performance shares to be reported on settlement. In addition, vesting accelerated immediately on 25,000 restricted stock previously granted to Mr. Benathen on January 27, 2022. The option vested and became exercisable in equal monthly tranches, based on the passage of time, over the 36 months following February 4, 2021. Read SEC document |
| January 27, 2023 Filed Jul 13, 2023 16:02 UTC | LifeMD, Inc. LFMD · Entity 6521 | Exercise / conversionRestricted Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-23-000047 · primary_doc.xml · derivative · entry 5 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock converts into common stock on a one-for-one basis. F3 · derivative.exercise_date: Restricted stock vested on January 27, 2023. F3 · derivative.expiration_date: Restricted stock vested on January 27, 2023. Read SEC document |
| January 27, 2023 Filed Jul 13, 2023 16:02 UTC | LifeMD, Inc. LFMD · Entity 6521 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-23-000047 · primary_doc.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 19:46 UTC | LifeMD, Inc. LFMD · Entity 6521 | Exercise / conversionRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-22-000005 · primary_doc.xml · derivative · entry 3 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · derivative.exercise_date: 25,000 RSUs vested on January 27, 2022. Of the remaining RSUs, 25,000 vest on January 27, 2023 and 25,000 vest on January 27, 2024. F1 · derivative.expiration_date: 25,000 RSUs vested on January 27, 2022. Of the remaining RSUs, 25,000 vest on January 27, 2023 and 25,000 vest on January 27, 2024. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 19:46 UTC | LifeMD, Inc. LFMD · Entity 6521 | GrantRestricted Stock Unit · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001362118-22-000005 · primary_doc.xml · derivative · entry 2 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · derivative.exercise_date: 25,000 RSUs vested on January 27, 2022. Of the remaining RSUs, 25,000 vest on January 27, 2023 and 25,000 vest on January 27, 2024. F1 · derivative.expiration_date: 25,000 RSUs vested on January 27, 2022. Of the remaining RSUs, 25,000 vest on January 27, 2023 and 25,000 vest on January 27, 2024. Read SEC document |
| January 27, 2022 Filed Jan 28, 2022 19:46 UTC | LifeMD, Inc. LFMD · Entity 6521 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001362118-22-000005 · primary_doc.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 30, 2021 Filed Dec 1, 2021 15:40 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock, par value $0.01 | 7,831 | $4.09 | $32,028.79 |
DisclosureSEC source: 0001362118-21-000049 · primary_doc.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,554 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.02 to $4.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 18:51 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 343 | $7.43 | $2,548.49 |
DisclosureSEC source: 0001362118-21-000029 · primary_doc.xml · nonDerivative · entry 5 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,723 Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 18:51 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 63 | $7.24 | $456.12 |
DisclosureSEC source: 0001362118-21-000029 · primary_doc.xml · nonDerivative · entry 4 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,380 Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 18:51 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 64 | $7.29 | $466.56 |
DisclosureSEC source: 0001362118-21-000029 · primary_doc.xml · nonDerivative · entry 3 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,317 Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 18:51 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 1,300 | $7.26 | $9,438.00 |
DisclosureSEC source: 0001362118-21-000029 · primary_doc.xml · nonDerivative · entry 2 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,253 Read SEC document |
| August 18, 2021 Filed Aug 18, 2021 18:51 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 1,297 | $7.23 | $9,377.31 |
DisclosureSEC source: 0001362118-21-000029 · primary_doc.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,953 Read SEC document |
| May 19, 2021 Filed May 19, 2021 19:19 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 317 | $8.81 | $2,791.91 |
DisclosureSEC source: 0001362118-21-000010 · primary_doc.xml · nonDerivative · entry 2 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,656 Read SEC document |
| May 19, 2021 Filed May 19, 2021 19:19 UTC | LifeMD, Inc. LFMD · Entity 6521 | PurchaseCommon Stock | 1,099 | $8.93 | $9,817.81 |
DisclosureSEC source: 0001362118-21-000010 · primary_doc.xml · nonDerivative · entry 1 Benathen Marc David · CIK 0001845258 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,339 F1 · shares: Jointly held with spouse F2 · balance_after: The shares beneficially owned have been adjusted to reflect an additional 240 shares not previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.